PD-L1 Epitope Mapping Peptide Array

The PD-L1 (Programmed cell death 1 ligand 1/CD274/B7-H1) Epitope Mapping Peptide Array is a semi-quantitative array displaying 261 synthesized peptides representing the full-length PD-L1. It is suitable for antibody epitope mapping and detection of IgG, IgA, IgM, IgE, etc. in serum, plasma, and many other liquid sample types.

For a service quote, please fill out the Epitope Mapping Array Quote Request Form.

As low as $0.00
In stock
Only %1 left
Catalog #:
PAH-PDL1-G1
-
+

Product Description

Specifications

Size 4 Sample Kit, 8 Sample Kit, 16 Sample Kit
Species Human
Accession Number Q9NZQ7
Protein Name / Synonyms PD-L1 / Programmed cell death 1 ligand 1 / CD274 / B7-H1
Quantitative/Semi-Quantitative Semi-Quantitative
Number of Targets Detected 261
Compatible Sample Types Plasma, Serum, Ascites, Hybridoma cell culture medium, Purified antibodies, Purified protein, DNA Aptamers, Other fluids
Solid Support Glass Slide
Method Of Detection Fluorescence Laser Scanner
Research Area Antibody Drug Development, Drug Antibody (DA) Detection
Estimated Lead Time 4-6 weeks
Shipping Type Blue ice
Storage -20°C
Amazon Gift Cards!

$5 Amazon gift card in every kit box purchased.

Peptide Information

Number of Peptides:
261
Peptide Length:
12-mer
Peptide Offset:
1-mer
Peptide Purity:
HPLC grade, >95% purity
Array Printing Replicate:
Triplicate

Peptide Sequence

1. FTVTVPKDLYVV 2. TVTVPKDLYVVE 3. VTVPKDLYVVEY 4. TVPKDLYVVEYG
5. VPKDLYVVEYGS 6. PKDLYVVEYGSN 7. KDLYVVEYGSNM 8. DLYVVEYGSNMT
9. LYVVEYGSNMTI 10. YVVEYGSNMTIE 11. VVEYGSNMTIEC 12. VEYGSNMTIECK
13. EYGSNMTIECKF 14. YGSNMTIECKFP 15. GSNMTIECKFPV 16. SNMTIECKFPVE
17. NMTIECKFPVEK 18. MTIECKFPVEKQ 19. TIECKFPVEKQL 20. IECKFPVEKQLD
21. ECKFPVEKQLDL 22. CKFPVEKQLDLA 23. KFPVEKQLDLAA 24. FPVEKQLDLAAL
25. PVEKQLDLAALI 26. VEKQLDLAALIV 27. EKQLDLAALIVY 28. KQLDLAALIVYW
29. QLDLAALIVYWE 30. LDLAALIVYWEM 31. DLAALIVYWEME 32. LAALIVYWEMED
33. AALIVYWEMEDK 34. ALIVYWEMEDKN 35. LIVYWEMEDKNI 36. IVYWEMEDKNII
37. VYWEMEDKNIIQ 38. YWEMEDKNIIQF 39. WEMEDKNIIQFV 40. EMEDKNIIQFVH
41. MEDKNIIQFVHG 42. EDKNIIQFVHGE 43. DKNIIQFVHGEE 44. KNIIQFVHGEED
45. NIIQFVHGEEDL 46. IIQFVHGEEDLK 47. IQFVHGEEDLKV 48. QFVHGEEDLKVQ
49. FVHGEEDLKVQH 50. VHGEEDLKVQHS 51. HGEEDLKVQHSS 52. GEEDLKVQHSSY
53. EEDLKVQHSSYR 54. EDLKVQHSSYRQ 55. DLKVQHSSYRQR 56. LKVQHSSYRQRA
57. KVQHSSYRQRAR 58. VQHSSYRQRARL 59. QHSSYRQRARLL 60. HSSYRQRARLLK
61. SSYRQRARLLKD 62. SYRQRARLLKDQ 63. YRQRARLLKDQL 64. RQRARLLKDQLS
65. QRARLLKDQLSL 66. RARLLKDQLSLG 67. ARLLKDQLSLGN 68. RLLKDQLSLGNA
69. LLKDQLSLGNAA 70. LKDQLSLGNAAL 71. KDQLSLGNAALQ 72. DQLSLGNAALQI
73. QLSLGNAALQIT 74. LSLGNAALQITD 75. SLGNAALQITDV 76. LGNAALQITDVK
77. GNAALQITDVKL 78. NAALQITDVKLQ 79. AALQITDVKLQD 80. ALQITDVKLQDA
81. LQITDVKLQDAG 82. QITDVKLQDAGV 83. ITDVKLQDAGVY 84. TDVKLQDAGVYR
85. DVKLQDAGVYRC 86. VKLQDAGVYRCM 87. KLQDAGVYRCMI 88. LQDAGVYRCMIS
89. QDAGVYRCMISY 90. DAGVYRCMISYG 91. AGVYRCMISYGG 92. GVYRCMISYGGA
93. VYRCMISYGGAD 94. YRCMISYGGADY 95. RCMISYGGADYK 96. CMISYGGADYKR
97. MISYGGADYKRI 98. ISYGGADYKRIT 99. SYGGADYKRITV 100. YGGADYKRITVK
101. GGADYKRITVKV 102. GADYKRITVKVN 103. ADYKRITVKVNA 104. DYKRITVKVNAP
105. YKRITVKVNAPY 106. KRITVKVNAPYN 107. RITVKVNAPYNK 108. ITVKVNAPYNKI
109. TVKVNAPYNKIN 110. VKVNAPYNKINQ 111. KVNAPYNKINQR 112. VNAPYNKINQRI
113. NAPYNKINQRIL 114. APYNKINQRILV 115. PYNKINQRILVV 116. YNKINQRILVVD
117. NKINQRILVVDP 118. KINQRILVVDPV 119. INQRILVVDPVT 120. NQRILVVDPVTS
121. QRILVVDPVTSE 122. RILVVDPVTSEH 123. ILVVDPVTSEHE 124. LVVDPVTSEHEL
125. VVDPVTSEHELT 126. VDPVTSEHELTC 127. DPVTSEHELTCQ 128. PVTSEHELTCQA
129. VTSEHELTCQAE 130. TSEHELTCQAEG 131. SEHELTCQAEGY 132. EHELTCQAEGYP
133. HELTCQAEGYPK 134. ELTCQAEGYPKA 135. LTCQAEGYPKAE 136. TCQAEGYPKAEV
137. CQAEGYPKAEVI 138. QAEGYPKAEVIW 139. AEGYPKAEVIWT 140. EGYPKAEVIWTS
141. GYPKAEVIWTSS 142. YPKAEVIWTSSD 143. PKAEVIWTSSDH 144. KAEVIWTSSDHQ
145. AEVIWTSSDHQV 146. EVIWTSSDHQVL 147. VIWTSSDHQVLS 148. IWTSSDHQVLSG
149. WTSSDHQVLSGK 150. TSSDHQVLSGKT 151. SSDHQVLSGKTT 152. SDHQVLSGKTTT
153. DHQVLSGKTTTT 154. HQVLSGKTTTTN 155. QVLSGKTTTTNS 156. VLSGKTTTTNSK
157. LSGKTTTTNSKR 158. SGKTTTTNSKRE 159. GKTTTTNSKREE 160. KTTTTNSKREEK
161. TTTTNSKREEKL 162. TTTNSKREEKLF 163. TTNSKREEKLFN 164. TNSKREEKLFNV
165. NSKREEKLFNVT 166. SKREEKLFNVTS 167. KREEKLFNVTST 168. REEKLFNVTSTL
169. EEKLFNVTSTLR 170. EKLFNVTSTLRI 171. KLFNVTSTLRIN 172. LFNVTSTLRINT
173. FNVTSTLRINTT 174. NVTSTLRINTTT 175. VTSTLRINTTTN 176. TSTLRINTTTNE
177. STLRINTTTNEI 178. TLRINTTTNEIF 179. LRINTTTNEIFY 180. RINTTTNEIFYC
181. INTTTNEIFYCT 182. NTTTNEIFYCTF 183. TTTNEIFYCTFR 184. TTNEIFYCTFRR
185. TNEIFYCTFRRL 186. NEIFYCTFRRLD 187. EIFYCTFRRLDP 188. IFYCTFRRLDPE
189. FYCTFRRLDPEE 190. YCTFRRLDPEEN 191. CTFRRLDPEENH 192. TFRRLDPEENHT
193. FRRLDPEENHTA 194. RRLDPEENHTAE 195. RLDPEENHTAEL 196. LDPEENHTAELV
197. DPEENHTAELVI 198. PEENHTAELVIP 199. EENHTAELVIPE 200. ENHTAELVIPEL
201. NHTAELVIPELP 202. HTAELVIPELPL 203. TAELVIPELPLA 204. AELVIPELPLAH
205. ELVIPELPLAHP 206. LVIPELPLAHPP 207. VIPELPLAHPPN 208. IPELPLAHPPNE
209. PELPLAHPPNER 210. ELPLAHPPNERT 211. LPLAHPPNERTH 212. PLAHPPNERTHL
213. LAHPPNERTHLV 214. AHPPNERTHLVI 215. HPPNERTHLVIL 216. PPNERTHLVILG
217. PNERTHLVILGA 218. NERTHLVILGAI 219. ERTHLVILGAIL 220. RTHLVILGAILL
221. THLVILGAILLC 222. HLVILGAILLCL 223. LVILGAILLCLG 224. VILGAILLCLGV
225. ILGAILLCLGVA 226. LGAILLCLGVAL 227. GAILLCLGVALT 228. AILLCLGVALTF
229. ILLCLGVALTFI 230. LLCLGVALTFIF 231. LCLGVALTFIFR 232. CLGVALTFIFRL
233. LGVALTFIFRLR 234. GVALTFIFRLRK 235. VALTFIFRLRKG 236. ALTFIFRLRKGR
237. LTFIFRLRKGRM 238. TFIFRLRKGRMM 239. FIFRLRKGRMMD 240. IFRLRKGRMMDV
241. FRLRKGRMMDVK 242. RLRKGRMMDVKK 243. LRKGRMMDVKKC 244. RKGRMMDVKKCG
245. KGRMMDVKKCGI 246. GRMMDVKKCGIQ 247. RMMDVKKCGIQD 248. MMDVKKCGIQDT
249. MDVKKCGIQDTN 250. DVKKCGIQDTNS 251. VKKCGIQDTNSK 252. KKCGIQDTNSKK
253. KCGIQDTNSKKQ 254. CGIQDTNSKKQS 255. GIQDTNSKKQSD 256. IQDTNSKKQSDT
257. QDTNSKKQSDTH 258. DTNSKKQSDTHL 259. TNSKKQSDTHLE 260. NSKKQSDTHLEE
261. SKKQSDTHLEET      

Application Notes

  • Identify high antigenicity epitopes for antibody production & vaccine development
  • Locate (auto)antigen epitopes of (auto)antibodies
  • Define the best antibody clone against the protein-of-interest
  • Perform epitope mutant analysis
  • Map B cell epitopes

Service Features

  • Small serum sample volume required (2 µl)
  • High density (simultaneously analyze hundreds of overlapping peptides)
  • High sensitivity
  • Large dynamic range
  • Suitable for high-throughput assays
  • High efficiency and accuracy
  • Affordable, quick and simple to use

Kit Components

  • RayBio® human PD-L1 protein peptide array
  • Blocking Buffer
  • Wash Buffer I
  • Wash Buffer II
  • Biotin-conjugated secondary antibody
  • Cy3 equivalent dye conjugated streptavidin
  • Array accessories (including slide incubation chamber assembly, gasket, adhesive plastic strips, etc.)

Other Materials Required

  • Distilled water
  • Small plastic boxes or containers
  • Orbital shaker or oscillating rocker
  • Pipettors, pipette tips and other common lab consumables
  • Aluminum foil
  • Laser fluorescence scanner

View Compatible Laser Scanners

Don't have a compatible scanner? RayBiotech now offers FREE scanning service for all RayBio glass slide antibody arrays! Learn More

Storage/Stability

Upon receipt, all kit components should be stored at -20 °C to -80 °C until ready to use. Stored properly, the kit will retain complete activity for up to 6 months.
Write Your Own Review
Your Rating
Submit a review for this product on Biocompare.com to earn an entry into a monthly raffle for one of five $100 Amazon gift cards!

Ask a Question

Display name:
Your location:*
This field is for validation purposes and should be left unchanged.